A Phase I Trial of Ublituximab, A Novel Glycoengineered Anti-CD20 mAb, In Combination With TGR-1202, A Next Generation PI3K Delta Inhibitor, In Patients With Chronic Lymphocytic Leukemia And Non-Hodgkin’s Lymphoma.

Drug Category : Array
Conference Category : Array
Lead Author : Lunning M, O'Brien S, et al.
Published Date : 21/07/2014
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/EPPLC2014-Poster2014.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top